BACKGROUND: Hepcidin-25 reduces iron absorption by binding to the intestinal iron transporter ferroportin and causing its degradation. Currently, little is known about the basal regulation of circulating hepcidin-25. In addition, although erythropoietin administration has been reported to decrease the circulating hepcidin concentration, information is limited regarding how other stimulators of erythropoiesis, such as growth hormone (GH), might alter hepcidin-25 concentrations. METHODS: We used a sensitive and specific hepcidin-25 dual-monoclonal antibody sandwich immunoassay to measure hepcidin-25 in healthy human volunteers at various time points throughout the day and during 3 days of fasting and subsequent refeeding. We also measured hepcidin-25 concentrations in healthy volunteers after GH administration. RESULTS: In healthy individuals, hepcidin-25 concentrations displayed a diurnal variation, with concentrations being lowest in the early morning and steadily increasing throughout the day before declining during the evening hours, a pattern that was not influenced by food intake. Prolonged fasting produced statistically significant increases in hepcidin-25 concentrations. Refeeding reversed this process, and GH administration markedly decreased hepcidin-25 concentrations. CONCLUSIONS: Our results indicate that in humans, hepcidin-25 exhibits diurnal changes that can be altered by prolonged fasting, which increases hepcidin-25 concentrations approximately 3-fold after 3 days of fasting, possibly owing to a suppression of erythropoiesis that may occur during the fasting state to preserve tissue iron concentrations. In contrast, GH administration decreased hepcidin-25 concentrations by approximately 65%, presumably by stimulating erythropoiesis. These results indicate that circulating hepcidin-25 concentrations display much more dynamic and rapid variation than might have been anticipated previously.
BACKGROUND:Hepcidin-25 reduces iron absorption by binding to the intestinal iron transporter ferroportin and causing its degradation. Currently, little is known about the basal regulation of circulating hepcidin-25. In addition, although erythropoietin administration has been reported to decrease the circulating hepcidin concentration, information is limited regarding how other stimulators of erythropoiesis, such as growth hormone (GH), might alter hepcidin-25 concentrations. METHODS: We used a sensitive and specific hepcidin-25 dual-monoclonal antibody sandwich immunoassay to measure hepcidin-25 in healthy human volunteers at various time points throughout the day and during 3 days of fasting and subsequent refeeding. We also measured hepcidin-25 concentrations in healthy volunteers after GH administration. RESULTS: In healthy individuals, hepcidin-25 concentrations displayed a diurnal variation, with concentrations being lowest in the early morning and steadily increasing throughout the day before declining during the evening hours, a pattern that was not influenced by food intake. Prolonged fasting produced statistically significant increases in hepcidin-25 concentrations. Refeeding reversed this process, and GH administration markedly decreased hepcidin-25 concentrations. CONCLUSIONS: Our results indicate that in humans, hepcidin-25 exhibits diurnal changes that can be altered by prolonged fasting, which increases hepcidin-25 concentrations approximately 3-fold after 3 days of fasting, possibly owing to a suppression of erythropoiesis that may occur during the fasting state to preserve tissue iron concentrations. In contrast, GH administration decreased hepcidin-25 concentrations by approximately 65%, presumably by stimulating erythropoiesis. These results indicate that circulating hepcidin-25 concentrations display much more dynamic and rapid variation than might have been anticipated previously.
Authors: Ellen M Smith; Jessica A Alvarez; Malcolm D Kearns; Li Hao; John H Sloan; Robert J Konrad; Thomas R Ziegler; Susu M Zughaier; Vin Tangpricha Journal: Clin Nutr Date: 2016-06-27 Impact factor: 7.324
Authors: Meredith A Atkinson; Stephen P Juraschek; Michael S Bertenthal; Barbara Detrick; Susan L Furth; Edgar R Miller Journal: Pediatr Nephrol Date: 2016-12-24 Impact factor: 3.714
Authors: Ellen M Smith; Jennifer L Jones; Jenny E Han; Jessica A Alvarez; John H Sloan; Robert J Konrad; Susu M Zughaier; Greg S Martin; Thomas R Ziegler; Vin Tangpricha Journal: JPEN J Parenter Enteral Nutr Date: 2017-12-11 Impact factor: 4.016
Authors: Dylan J Harney; Amy T Hutchison; Zhiduan Su; Luke Hatchwell; Leonie K Heilbronn; Samantha Hocking; David E James; Mark Larance Journal: Mol Cell Proteomics Date: 2019-07-15 Impact factor: 5.911
Authors: Wendy P J den Elzen; Anton J M de Craen; Erwin T Wiegerinck; Rudi G J Westendorp; Dorine W Swinkels; Jacobijn Gussekloo Journal: Haematologica Date: 2012-10-12 Impact factor: 9.941
Authors: Sophie Waldvogel-Abramowski; Gérard Waeber; Christoph Gassner; Andreas Buser; Beat M Frey; Bernard Favrat; Jean-Daniel Tissot Journal: Transfus Med Hemother Date: 2014-05-12 Impact factor: 3.747
Authors: Claire E Badenhorst; Brian Dawson; Gregory R Cox; Marc Sim; Coby M Laarakkers; Dorine W Swinkels; Peter Peeling Journal: Eur J Appl Physiol Date: 2016-07-05 Impact factor: 3.078
Authors: Lieke Uijterschout; Magnus Domellöf; Staffan K Berglund; Micky Abbink; Paul Vos; Lyanne Rövekamp; Bart Boersma; Carina Lagerqvist; Cisca Hudig; Johannes B van Goudoever; Frank Brus Journal: Pediatr Res Date: 2015-12-16 Impact factor: 3.756